Search

This article discusses the use of deep learning and unsupervised methods to classify medical images, specifically focusing on the classification of chimeric antigen receptor T cells (CAR-T) and tumor cocultures. The authors propose a novel approach that combines image clustering with an explanation of how these clusters are formed. They also introduce a unique dataset focused on cell data, highlighting the developmental patterns of cancer cells and T cells under various experimental conditions. The study compares different architectural models on this dataset and demonstrates the superior performance of their proposed architecture. This research contributes to the field of image classification and offers new possibilities for understanding complex biological processes through computer vision. [Extracted from the article]

Researchers at the Dana-Farber Cancer Institute have developed a technique to prevent relapse after CAR T-cell therapy, a breakthrough treatment for certain forms of cancer. The technique, called CAR-Enhancer (CAR-E), spurs CAR T cells to be more active and persist longer in the body, allowing them to eliminate all tumor cells and form a memory of the cancer. In laboratory and animal studies, CAR-E therapy successfully eradicated tumor cells, paving the way for future clinical trials. The researchers hope that CAR-E therapy can be easily integrated into the care of patients receiving CAR T-cell therapies. [Extracted from the article]

A patent has been issued to Thunder Biotech Inc. for transgenic macrophages, chimeric antigen receptors, and associated methods. The patent describes the role of macrophages in cancer development and progression, as well as their polarization into M1 and M2 phenotypes. M1 macrophages have pro-inflammatory properties and can suppress tumor growth, while M2 macrophages have anti-inflammatory properties and promote tissue repair and angiogenesis. The patent also discusses the engineering of macrophages using chimeric antigen receptors to polarize them towards the desired phenotype. This information is valuable for understanding the immune system's role in cancer and developing potential therapeutic strategies. [Extracted from the article]

The article discusses the development of synthetic immune chimeric antigen receptor T (CAR T) cells as a treatment for cancer, including through offering a diagram. An overview of the genetic engineering of CAR T cells to treat cancer, including the genetic modification of T cells to target the antigen, is provided.

A recent study conducted by Bristol-Myers Squibb Company explores the challenges and lessons learned in the development of autologous chimeric antigen receptor (CAR) T-cell therapy from a statistical perspective. CAR T-cell therapy is a form of gene therapy where a patient's T cells are genetically modified to better recognize target antigens. Despite the progress made in CAR T-cell therapies, there are still statistical challenges that need to be addressed, such as dose finding strategies, the use of real-world data, and long-term safety analysis. This research aims to summarize and address these statistical hurdles based on the development of the six approved CAR T-cell products. [Extracted from the article]

A recent study conducted by researchers at the China-Japan Union Hospital of Jilin University explores the potential of CAR-based immunotherapy for breast cancer treatment. The study highlights the limitations of current treatment modalities for triple-negative breast cancer (TNBC) and suggests that CAR-T cell therapy, which has shown promise in hematological tumors, could be a viable option. The researchers discuss the challenges posed by the tumor microenvironment and the potential use of CAR-macrophages, CAR-NK cells, and CAR-mesenchymal stem cells (MSCs) for breast cancer treatment. They also explore the use of CAR-expressing exosomes as a potential treatment modality. Further research is needed to fully understand the effectiveness and safety of CAR-based immunotherapy for breast cancer. [Extracted from the article]

A report from Henan University in China discusses the challenges of tumor immune escape in cancer treatment and the potential of chimeric antigen receptor (CAR) T-cell therapy. The researchers developed a mathematical model to study the interactions between tumor cells, immune escape tumor cells, and T lymphocytes. Bifurcation analysis revealed the existence of backward and saddle-node bifurcations, and the model exhibited bistability. Simulation studies confirmed the analysis results and showed that CAR T-cell therapy can reduce the size of immune escape tumors, with the treatment effect depending on the therapy's strength. [Extracted from the article]

A patent application has been published online for a method of high-throughput screening of chimeric antigen receptors (CARs). The method involves creating a library of CARs by combining different sequences, and then expressing these CARs on the surface of cells. The CAR-cell library is then screened to identify sequences that have desired functions. This method can be used to efficiently identify CAR candidates for clinical use by evaluating their affinity binding, downstream signaling, and gene expression modulation. [Extracted from the article]

A new study published in Cell suggests that a CRISPR RNA-editing platform called Multiplexed Effector Guide Arrays (MEGA) could enhance cell therapies for cancer. Researchers at Stanford University used MEGA to modify the RNA of cells, which improved immune cell metabolism and their ability to target tumors. Unlike previous gene-editing platforms, MEGA cuts RNA instead of DNA, allowing for reversible changes to gene expression in T cells. The researchers hope that this tool can eventually be used in clinical settings to improve cancer treatments. [Extracted from the article]

A recent study led by Memorial Sloan Kettering Cancer Center and Cold Spring Harbor Laboratory has found that chimeric antigen receptor (CAR) T cells, which have been successful in treating blood cancers, may also hold promise for treating age-related diseases caused by the accumulation of senescent cells. The study showed that an infusion of CAR T cells targeting senescent cells improved metabolic function in older mice and mice with a high-fat diet. The treatment also prevented metabolic decline in young, healthy mice. Further research is needed to determine if this approach can extend lifespan and improve overall health. [Extracted from the article]

Researchers at the Children's Hospital of Philadelphia (CHOP) have made a breakthrough in the field of cancer gene therapy. They have discovered the three-dimensional protein structure that allows peptide-centric chimeric antigen receptors (PC-CARs) to recognize the "backbones" of human leukocyte antigens (HLAs), which are responsible for distinguishing proteins in the immune system. This discovery will enable the design of PC-CARs that can target multiple HLAs, increasing the efficiency of therapeutic design and potentially treating more complex and difficult-to-treat tumors. The findings have been published in the journal Science Immunology. CHOP is currently recruiting patients for clinical trials based on their HLA genotypes to further explore the effectiveness of PC-CARs in treating rare and complex forms of cancer. [Extracted from the article]

A recent study conducted at Memorial Sloan Kettering Cancer Center has shown that disrupting a single gene in CAR T cells, a type of immunotherapy, can enhance their effectiveness in fighting tumors. The researchers found that disrupting the gene SUV39H1 restored the expression of multiple genes that help sustain the longevity of the CAR T cells. This approach could potentially expand the pool of patients eligible for CAR T cell therapy and reduce side effects. The study used gene-editing tool CRISPR/Cas9 to alter the gene in human CAR T cells and observed positive results in mice with leukemia and prostate cancer. Further research is needed to confirm the safety and efficacy of this approach in humans. [Extracted from the article]

A report from the Universidad Autonoma de Nuevo Leon discusses the use of chimeric antigen receptor (CAR) technology in cancer treatment. The researchers explain the structure and different generations of CAR-T cells, as well as the manufacturing approaches for these cells. They also highlight the potential of CAR-T cells to treat not only cancer but other chronic diseases. The report concludes by summarizing the use of CAR technology in other immune cells such as natural killer cells, macrophages, and dendritic cells. [Extracted from the article]

SUVs (so-called sport utility vehicles) use more fuel per kilometre than standard cars - according to the International Energy Agency, up to 25% more. How heavier, costlier SUVs and utes took over Australia's roads SUVs outsell passenger cars 3 to 1 As recently as 2012, more than half the new vehicles sold in Australia were "passenger cars" - the standard low-slung cars of the type we were used to. [Extracted from the article]

Probiotics could be the key to making universal chimeric antigen receptor T cell therapies work for solid tumors, new research has suggested. [ABSTRACT FROM AUTHOR]

3.5 Big price and weight hike ever the coupe but cures most cf the previous car's ills F-Type V6 AWD Coupe F-Type V6 S AWD 3.0 Turbo four-ppt is frugal and mure flexible than V6 despite lacking pace and the V6's chassis upgrades 3.5 Twin-turbo VB matches old V8 for grunt, but it feels its size and the VB is more appealing. [Extracted from the article]

TOO FAST FOR THE RULES: THE R32 GT-R WAS THE BEAST THAT ATE BATHURST, YET IT WAS FAR MORE AN AUSTRALIAN CAR THAN IT'S OFTEN GIVEN CREDIT FOR. V8 legends Richards and Skaife, guided by acclaimed Nissan team boss Fred Gibson, established the GT-R in Australian motor racing folklore -- and infamy -- by overwhelming the opposition in '91/92. Winner of five touring car titles and six Bathurst 1000s, Skaife, who has been heavily aligned with Nissan and Holden in his racing career, also remembers the R32 Skyline GT-R road car fondly. PHOTO (COLOR): Touring car champion Mark Skaife and guru team owner Fred Gibson recall the glory days when they ruled local Group A racing with the R32. [Extracted from the article]

Keywords: Antigen Receptors; Blood Protein Disorders; Cancer; Clinical Research; Clinical Trials and Studies; Health and Medicine; Hematologic Diseases and Conditions; Hematology; Hemic and Lymphatic Diseases and Conditions; Hemorrhagic Disorders; Hemostatic Disorders; Immunologic Receptors; Immunoproliferative Disorders; Lymphoproliferative Disorders; Membrane Proteins; Multiple Myeloma; Myeloma; Oncology; Paraproteinemias; Vascular Diseases and Conditions EN Antigen Receptors Blood Protein Disorders Cancer Clinical Research Clinical Trials and Studies Health and Medicine Hematologic Diseases and Conditions Hematology Hemic and Lymphatic Diseases and Conditions Hemorrhagic Disorders Hemostatic Disorders Immunologic Receptors Immunoproliferative Disorders Lymphoproliferative Disorders Membrane Proteins Multiple Myeloma Myeloma Oncology Paraproteinemias Vascular Diseases and Conditions 953 953 1 07/03/23 20230703 NES 230703 2023 JUL 3 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Investigators discuss new findings in multiple myeloma. Antigen Receptors, Blood Protein Disorders, Cancer, Clinical Research, Clinical Trials and Studies, Health and Medicine, Hematologic Diseases and Conditions, Hematology, Hemic and Lymphatic Diseases and Conditions, Hemorrhagic Disorders, Hemostatic Disorders, Immunologic Receptors, Immunoproliferative Disorders, Lymphoproliferative Disorders, Membrane Proteins, Multiple Myeloma, Myeloma, Oncology, Paraproteinemias, Vascular Diseases and Conditions. [Extracted from the article]

(Bloomberg) -- Picking Out the Pedestrian May Have Foiled Uber's Robot Ride Experts say that the sophisticated sensors on the autonomous vehicle almost certainly detected the woman pushing her bicycle laden with bags along the median, close to the road. After the Uber collision, the car continued traveling at 38 miles per hour, according to the Tempe police chief, and the driver told police he wasn't aware of the pedestrian until the car collided with her. [Extracted from the article]

In the first section, strategies for modifying CAR-Ts using gene-editing technologies or combining them with other anti-tumor drugs to enhance the efficacy of CAR-T therapy are introduced. Keywords: Antigen Receptors; Biological Therapy; Biomedical Engineering; Biomedicine; Biotechnology; Cell Therapy; Drugs and Therapies; Immunologic Receptors; Membrane Proteins EN Antigen Receptors Biological Therapy Biomedical Engineering Biomedicine Biotechnology Cell Therapy Drugs and Therapies Immunologic Receptors Membrane Proteins 401 401 1 06/12/23 20230616 NES 230616 2023 JUN 13 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Researchers detail new data in cell therapy. [Extracted from the article]

Exploratory gene expression and immunophenotypic analysis also revealed that objective response occurred in patients with a moderately inflamed tumor microenvironment and modest PD-1 expression, meriting further investigation of which patient characteristics will determine who is more likely to benefit from this treatment. Keywords: Bioengineering; Biotechnology; Cancer; Cancer Gene Therapy; Clinical Research; Clinical Trials and Studies; Drugs and Therapies; Engineered Viruses; Engineering; Gene Therapy; Glioblastomas; Health and Medicine; Immunologic Agents; Immunotherapy; Monoclonal Antibodies; Oncology; Pembrolizumab Therapy; Pharmaceuticals; Post-Trial Research; Therapy; University of Texas M. D. Anderson Cancer Center; Virology; Viruses EN Bioengineering Biotechnology Cancer Cancer Gene Therapy Clinical Research Clinical Trials and Studies Drugs and Therapies Engineered Viruses Engineering Gene Therapy Glioblastomas Health and Medicine Immunologic Agents Immunotherapy Monoclonal Antibodies Oncology Pembrolizumab Therapy Pharmaceuticals Post-Trial Research Therapy University of Texas M. D. Anderson Cancer Center Virology Viruses 18 18 1 05/29/23 20230529 NES 230529 2023 MAY 29 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- HOUSTON - Intratumoral delivery of an engineered oncolytic virus (DNX-2401) targeting glioblastoma (GBM) cells combined with subsequent immunotherapy was safe and improved survival outcomes in a subset of patients with recurrent GBM, according to results from a multi-institutional Phase I/II clinical trial co-led by researchers at The University of Texas MD Anderson Cancer Center and the University of Toronto. [Extracted from the article]

CAR T therapy has anti-cancer effect on DIPG WEHI researchers have found promise in treating DIPG with an innovative new immunotherapy treatment, called CAR T therapy. Keywords: Anticancer Agents; Biological Therapy; Biomedical Engineering; Biomedicine; Biotechnology; Brain Cancer; Cancer; Cell Therapy; Clinical Research; Clinical Trials and Studies; Drugs and Therapies; Genetics; Health and Medicine; Immunotherapy; Oncology; Pediatrics; Pre-Trial Research; Protective Agents; Walter and Eliza Hall Institute EN Anticancer Agents Biological Therapy Biomedical Engineering Biomedicine Biotechnology Brain Cancer Cancer Cell Therapy Clinical Research Clinical Trials and Studies Drugs and Therapies Genetics Health and Medicine Immunotherapy Oncology Pediatrics Pre-Trial Research Protective Agents Walter and Eliza Hall Institute 94 94 1 05/22/23 20230523 NES 230523 2023 MAY 23 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Children with an inoperable type of brain cancer may benefit from an advanced immunotherapy treatment, according to new research. [Extracted from the article]

Rochester, United Kingdom, Europe, Antigen Receptors, Biotechnology, Cancer, Health and Medicine, Hematology, Immunologic Receptors, Leukemia, Membrane Proteins, Oncology, Xenografts, Xenotransplantion, Acute Lymphoblastic Leukemia Keywords: Rochester; United Kingdom; Europe; Acute Lymphoblastic Leukemia; Antigen Receptors; Biotechnology; Cancer; Health and Medicine; Hematology; Immunologic Receptors; Leukemia; Membrane Proteins; Oncology; Xenografts; Xenotransplantion EN Rochester United Kingdom Europe Acute Lymphoblastic Leukemia Antigen Receptors Biotechnology Cancer Health and Medicine Hematology Immunologic Receptors Leukemia Membrane Proteins Oncology Xenografts Xenotransplantion 1959 1959 1 04/17/23 20230418 NES 230418 2023 APR 21 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators discuss new findings in Biotechnology - Xenografts. [Extracted from the article]

At the time, GM was the biggest company in the world and the place to be, but Pontiac struggled with its brand identity and wasn't connecting with America's youth—suddenly a huge new consumer driving the country's emerging car culture. [ABSTRACT FROM AUTHOR]

(Bloomberg View) -- Don't Want Your Car Hacked? All the frenzy over car-hacking would make more sense if the risk weren't so easy to reduce: Just drive a simple car. [Extracted from the article]